Coherus BioSciences (CHRS) Narrows Q4 Loss
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.65 -1.2%
Revenue Growth %: +40.6%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +40.6%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.47), versus ($3.68) reported last year. Revenue for the quarter came in at $6.5 million, versus $1.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
- Venture Global exports 127 LNG cargos in Q2 2026
- Fed: A Few Saw Case For Raising Rates At June Fomc Meeeting
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
